NERV Minerva Neurosciences Inc

8.66
+0.24  (+3%)
Previous Close 8.42
Open 8.48
Price To Book 5.04
Market Cap 337,960,579
Shares 39,025,471
Volume 328,819
Short Ratio
Av. Daily Volume 266,606

NewsSee all news

  1. Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature

    $13 Million Series A Financing from Medicxi Development pipeline based on co-founders' research into disconnecting tumour cell networks Initial focus on glioblastoma, expanding to other solid tumours New Nature

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 3Q 2019.
MIN-202 (seltorexant) vs quetiapine
Major Depressive Disorder
Phase 2b data May 13, 2019 noted p-value was 0.083.
MIN-202 (seltorexant)
Major Depressive Disorder
Phase 2b data due 4Q 2019.
MIN-117
Major Depressive Disorder
Phase 3 data due 4Q 2019.
Roluperidone (MIN-101)
Schizophrenia
Phase 2b data June 24, 2019 met primary endpoint.
MIN-202 (seltorexant)
Primary insomnia

Latest News

  1. Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature

    $13 Million Series A Financing from Medicxi Development pipeline based on co-founders' research into disconnecting tumour cell networks Initial focus on glioblastoma, expanding to other solid tumours New Nature